TC BioPharm Inks LOI To Acquire Privately-held CAR-T Therapy Innovator
(RTTNews) - Biotechnology company TC BioPharm (Holdings) plc (TCBP) announced Monday the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors.
This agreement is the second such agreement in as many months that shows TC BioPharm's commitment to its M&A strategy aimed at expanding its therapeutic platform.
CAR T-cell therapy modifies a patient's own immune cells to provide a heightened ability to identify and eliminate cancer cells.
The target acquisition has developed a number of proprietary approaches to re-engineer CARs to better target solid tumors. The Company has generated pre-clinical proof of concept data that demonstrates the therapeutic potential of its lead CAR-T candidate for a range of solid tumors including colorectal, pancreatic, mesothelioma, ovarian and breast cancer
In addition, the target acquisition is also developing a novel, allogeneic CAR-T for the treatment of autoimmune diseases.
TC BioPharm Unveils Corporate Restructuring Plan; To Cut Up To 30% Of Workforce
TSX Ends Notably Higher, Gains 0.7% In Week
Dollar Retreats After Early Gains
Swiss Market Ends On Firm Note Again
Major European Markets Close Weak On Interest Rate Concerns
U.S. Dollar Lower On Rate Cut Expectations
Canadian Market Up In Positive Territory; Materials Shares Rally
